clinical trials

News

Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.

News

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.

News

Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.

News

Neuralink has been given regulatory approval to start a new trial of its brain implant to see if it can be used to control a robotic arm